Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7281690 | 0.96 | NR3C1 (0.51) | NR3C1KCNA5KCNH2CYP1A2CYP3A4 | |
| SCHEMBL9208031 | 0.90 | CYP19A1 (0.56) | KCNA5KCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9213281 | 0.84 | HTR2A (0.48) | NR3C1SLC6A4HTR1A | |
| SCHEMBL4351623 | 0.84 | MPO (0.54) | SLC6A4HTR1A | |
| SCHEMBL9215791 | 0.84 | SLC6A4 (0.52) | SLC6A4HTR1AMAPTTDP1 | |
| SCHEMBL16433094 | 0.83 | MAPT (0.57) | CYP1A2CYP2D6CYP2C9SMN1; SMN2SLC6A4 | |
| SCHEMBL10846889 | 0.82 | NR3C1 (0.49) | NR3C1KCNA5KCNH2SMN1; SMN2SIRT1 | |
| SCHEMBL5338731 | 0.82 | SLC6A4 (0.55) | KCNA5KCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18926552 | 0.81 | PSMD10 (0.45) | CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL16433322 | 0.81 | SLC6A4 (0.55) | SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027607-B1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20180179188-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND METHODS OF USE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-06-28 | — | — | US | disclosed |
| US-9714232-B2 | Substituted piperazine compounds and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-9598401-B2 | Substituted heteroaryl compounds and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-21 | — | — | US | disclosed |
| WO-2017044742-A1 | NOVEL CYP34A-SPECIFIC INHIBITORS AND METHODS OF USING SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-16 | — | — | WO | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160244429-A1 | Substituted Piperazine Compounds And Methods Of Use Thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-25 | — | — | US | disclosed |
| EP-3027607-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2016-06-08 | — | — | EP | disclosed |
| US-20160083370-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-03-24 | — | — | US | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| WO-2004089942-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-1432420-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | Acadia Pharmaceuticals Inc. (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003028650-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0464558-B1 | Antimigraine alkoxypyrimidine derivatives | BRISTOL MYERS SQUIBB CO (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
| EP-0464558-A1 | Antimigraine alkoxypyrimidine derivatives | Bristol-Myers Squibb Company (US) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244429-A1 | Substituted Piperazine Compounds And Methods Of Use Thereof | HTR5A, HTR2A, HTR2C | NR3C1 360/4885KCNA5 1338/4885KCNH2 1297/4885 |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | NR3C1 592/4885KCNA5 120/4885KCNH2 316/4885 |
| US-20160083370-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HTR3B, HTR3A, HTR2C | NR3C1 229/4885KCNA5 2123/4885KCNH2 3205/4885 |
| US-20180179188-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND METHODS OF USE AND USE THEREOF | HTR5A, HTR2C, TPH1 | NR3C1 752/4885KCNA5 702/4885KCNH2 1768/4885 |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | NR3C1 592/4885KCNA5 120/4885KCNH2 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.